Abstract: This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection. In an embodiment, this disclosure provides a particle heater comprising a carrier admixed with a material that interacts with an exogenous source; wherein the material absorbs and converts the energy from the exogenous source into heat, then the heat travels outside the particle heater to induce localized hyperthermia at a temperature sufficient to selectively kill unwanted cells, and further wherein the particle heater structure is constructed such that it passes the Extractable Cytotoxicity Test.

Abstract: This invention provides particles encapsulating colorant that do not produce functional effects or remove functional effects until they are triggered by contacting with at least one exogenous source. The particles in this invention minimize toxic effects the body of the colorant and the material that interacts with an exogenous source as well as minimize body chemicals from degrading both the colorant and the material that interacts with an exogenous source inside the particle.

Abstract: The disclosure provides biosensors, diagnostic compositions, diagnostic particles, theranostic particles thereof and methods of use thereof to detect drug resistant microbes and destroy them using an exogenous source.

Abstract: This invention provides particles encapsulating active agent that do not produce functional effects or remove functional effects until they are triggered by contacting with at least one exogenous source. The particles in this invention minimize toxic effects to the body of the active agent and the material that interacts with an exogenous source as well as minimize body chemicals from degrading both the active agent and the material that interacts with an exogenous source inside the particle.

Abstract: The disclosure describes a heat delivery medium and composition for biomedical applications with controlled conversion of energy from an exogenous source to heat.

Abstract: This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection.

Abstract: The present invention provides crystalline Form I, Form II, Form III, Form IV, Form V, Form V-A, Form VI, Form VII, and Form VIII of palbociclib, processes for their preparation, pharmaceutical compositions comprising these crystalline forms, and their use for the treatment of cyclin-dependent kinase associated diseases.

Abstract: The present invention relates to a process for the preparation of palbociclib utilizing a silyl-protected crotonic acid derivative to produce a silyl-protected 2-chloro-4-(cyclopentylamino)-5-(1-methyl-2-carboxy-ethen-1-yl)pyrmidine followed by intramolecular cyclization of the pyrmidine intermediate to produce 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one which is then converted to palbociclib.

Abstract: The invention relates to blood substitute compositions, and methods of use thereof. Described herein are compositions in which hemoglobin is maintained substantially in the reduced form of hemoglobin as opposed to the oxidized methemoglobin form through inclusion of an oxido-reductase enzyme and reducing agent within a vesicle with the hemoglobin. The vesicles additionally can comprise a dismutase, a catalase, and an electron acceptor, each of which contribute to either the maintenance of hemoglobin in the active oxygen carrying state or provide a benefit not achieved with free hemoglobin.

Abstract: The present invention relates to a process for the preparation of ceftaroline salts or hydrates thereof.

Abstract: The invention relates to blood substitute compositions, and methods of use thereof. Described herein are compositions in which hemoglobin is maintained substantially in the reduced form of hemoglobin as opposed to the oxidized methemoglobin form through inclusion of an oxido-reductase enzyme and reducing agent within a vesicle with the hemoglobin. The vesicles additionally can comprise a dismutase, a catalase, and an electron acceptor, each of which contribute to either the maintenance of hemoglobin in the active oxygen carrying state or provide a benefit not achieved with free hemoglobin.

Abstract: The present invention relates to process and intermediates for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine.

Abstract: The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II, wherein R is a protecting group, with a phosphorohalidate in the presence of a base and a catalytic amount of dialkylaminopyridine.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity, which comprises dissolving crude imipenerm in warm water to which some base has been added to obtain a solution, subjecting the resultant solution to activated carbon treatment, and adding an organic solvent to precipitate imipienem monohydrate as a crystalline product.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyophilized; and isolating the pure crystalline imipenem monohydrate from the reaction mixture thereof.

Abstract: The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity.

Abstract: The present invention relates to an improved, cost effective and industrially advantageous process for the preparation of imipenem.

Abstract: The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I.

Abstract: This invention relates to reactive derivatives of 2-(2-aminothiazol-4-yl)-2-methoxyimino acetic acid and 1H-tetrazol-1-acetic acid of the following general formula I, ##STR1## wherein ##STR2## as well as to use thereof in the manufacture of cephalosporin antibiotics such as cefotaxime, ceftriaxone and cefazolin.